Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma
Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors
A Novel Conditional Active Biologic Anti-EpCAM x Anti-CD3 Bispecific Antibody with Synergistic Tumor Selectivity for Cancer Immunotherapy
Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors
Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors
Novel conditionally active biologic (CAB) antibodies
